Results 91 to 100 of about 124,170 (327)
Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity
KG‐FP‐003, a highly potent TEAD‐YAP PROTAC derived from the patented inhibitor is developed. It selectively degrades endogenous TEAD proteins in HiBiT systems without IMiD‐related off‐target effects. Screening across 867 cancer cell lines revealed broad and superior anti‐tumor activity, highlighting its therapeutic potential through targeted TEAD ...
Linhui Cao +25 more
wiley +1 more source
The high efficiency of baculovirus infection is partially explained by the ability of the virus to suppress host defense machinery connected with the apoptosis pathway.
Oberemok Volodymyr V. +7 more
doaj +1 more source
The how and why of lncRNA function: An innate immune perspective. [PDF]
Next-generation sequencing has provided a more complete picture of the composition of the human transcriptome indicating that much of the "blueprint" is a vastness of poorly understood non-protein-coding transcripts.
Carpenter, Susan +2 more
core
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging [PDF]
Small interfering RNA (siRNA) molecules are potent effectors of post-transcriptional gene silencing. Using noninvasive bioluminescent imaging and a mathematical model of siRNA delivery and function, the effects of target-specific and treatment-specific ...
Bartlett, Derek W., Davis, Mark E.
core +1 more source
This study employed tRNASUAG, an anticodon‐engineered tRNA (ACE‐tRNA), to introduce a phosphorylatable serine into the C‐terminal domain of HBc by reading through its stop codon, thereby potentially promoting the ubiquitin‐proteasome degradation of HBc, and subsequently inhibiting HBV replication. Through a tRNASUAG‐gHBV1‐tRNASUAG‐gHBV2‐tRNASUAG tandem
Xingwen Yang +7 more
wiley +1 more source
Delivery is key: lessons learnt from developing splice‐switching antisense therapies
The use of splice‐switching antisense therapy is highly promising, with a wealth of pre‐clinical data and numerous clinical trials ongoing. Nevertheless, its potential to treat a variety of disorders has yet to be realized. The main obstacle impeding the
Caroline Godfrey +17 more
doaj +1 more source
Antisense-mediated exon skipping is currently in clinical development for Duchenne muscular dystrophy (DMD) to amend the consequences of the underlying genetic defect and restore dystrophin expression. Due to turnover of compound, transcript, and protein,
Ingrid E C Verhaart +9 more
doaj +1 more source
Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture Models. [PDF]
Systemic delivery of antisense oligonucleotides (AO) for DMD exon skipping has proven effective for reframing DMD mRNA, rescuing dystrophin expression, and slowing disease progression in animal models.
Barthélémy, Florian +6 more
core +1 more source
The restoration of blood flow following surgical decompression for degenerative cervical myelopathy (DCM) significantly contributes to the amelioration of neurological deficits. This study identifies AGAPIR, an angiogenesis‐associated PIWI‐interacting RNA, enhances angiogenesis and motor function recovery post‐spinal cord decompression in a mouse model
Yongheng Xie +8 more
wiley +1 more source
PCSK9 acts as a molecular chaperone promoting LIN28A lysosomal degradation. LIN28A elevates transcription factor HES5, increasing JMY expression. PCSK9 loss causes neural tube defects (NTDs) by disrupting the LIN28A/HES5/JMY axis, and high JMY disorganizes the neural progenitor cell microfilament network, leading to incomplete neural tube structure in ...
Xiaoshuai Li +6 more
wiley +1 more source

